Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms, Hereditary Nonpolyposis 2Colorectal Neoplasms 2Recurrence 1Neoplasms 1Lymphoma, Follicular 1Colonic Neoplasms 1Colitis, Ulcerative 1Adenoma 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Mesalamine × Clear all
NCT01894685 2015-12-08

Mesalazine Effects in Sporadic Colorectal Adenoma Patients

UMC Utrecht

Phase 2 Completed
74 enrolled

Adenoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡